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Development of therapeutic vaccines is one of the major areas of tumour immunotherapy today. However, clinical trials of
peptide-based cancer vaccines have rarely resulted in tumour regression. This failure might be due to an insufﬁcient induction
of cytotoxic T lymphocytes in the current regimes, in which cytotoxic T lymphocytes-precursors in pre-vaccination peripheral
blood mononuclear cells are not measured. Initiation of immune-boosting through vaccination could be better than that of
immune-priming with regard to induction of prompt and strong immunity. If this is also the case for therapeutic vaccines, pre-
vaccination measurement of peptide-speciﬁc cytotoxic T lymphocytes-precursors will be important. In the present study, we
investigated whether cytotoxic T lymphocytes-precursors reacting to 28 kinds of peptides of vaccine candidates (13 and 15
peptides for HLA-A24
+ and HLA-A2
+ patients, respectively) were detectable in pre-vaccination peripheral blood
mononuclear cells of 80 cancer patients. Peptide-speciﬁc cytotoxic T lymphocytes-precursors were found to be detectable
in peripheral blood mononuclear cells of the majority of cancer patients (57 out of 80 cases, 71%). The mean numbers of
positive peptides were 2.0 peptides per positive case. Peripheral blood mononuclear cells incubated with positive peptides,
not with negative peptides, showed signiﬁcant levels of HLA-class-I-restricted cytotoxicity to cancer cells. The proﬁles of
positive peptides entirely varied among patients, and were not inﬂuenced by the cancer origin. These results may provide a
scientiﬁc basis for the development of a new approach to cancer immunotherapy, e.g.) cytotoxic T lymphocytes-precursor-
oriented peptide vaccine.
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Recent advances in molecular biology and tumour immunology
have allowed for identiﬁcation of a large number of genes and anti-
genic peptides recognised by cytotoxic T lymphocytes (CTLs),
thereby introducing the possibility of a peptide-based cancer
vaccine (Bruggen et al, 1991; Kawakami et al, 1994; Fisk et al,
1995; Correale et al, 1998). Preventive vaccine protocols for patho-
genic microbes generally consist of three steps; priming, boosting
and challenging (Amara et al, 2001). It usually takes several months
for priming, which is consistent with the present results of our
clinical trial using SART3-peptide vaccine (Miyagi et al, 2001).
Although increased CTL activity has been obtained in the majority
of cancer patients vaccinated with the peptides, clinical responses
have rarely been obtained in these patients in either previous
studies of melanoma patients (Rosenberg et al, 1998; Marchand
et al, 1999; Wang et al, 1999; Gajewski et al, 2001), or our study
of epithelial cancer patients (Miyagi et al, 2001).
One explanation for the failure to obtain clinical responses would
be the time-lag needed for priming of anti-tumour response, given
that the expected survival of most advanced cancer patients under
these regimens is 6–9 months. Therefore, developing a new protocol
for obtaining tumour regression in these cancer patients is necessary.
One protocol might be a pre-vaccination measurement of peptide-
speciﬁc CTL-precursors in the circulation of cancer patients, followed
by administration of CTL-precursor-oriented peptide vaccine. This
protocol may more rapidly increase CTL activity in post-vaccination
peripheral blood mononuclear cells (PBMCs). Pre-vaccination
measurement of CTL-precursors could also be an important factor
in the generation of strong immune response, since Langerhans cells
presenting peptides need to meet peptide-speciﬁc CTL-precursors
within 2 days at the regional lymph nodes to activate CTLs (Janeway
et al, 1999). Further, recent studies on memory CD8
+T cells suggest
that the main effect of vaccine boosters is to increase the number of
antigen-speciﬁc memory T cells to one that confers better protection
(Kaech and Ahmed, 2001; Finn and Lotze, 2001; Stipdonk et al, 2001).
In the present study, we investigated whether peptide-speciﬁc
CTL-precursors are detectable in pre-vaccination PBMCs from
cancer patients, and report herein that CTL-precursors reacting
to cancer-related peptides are detectable in prevaccination PBMCs
of the majority of cancer patients.
MATERIALS AND METHODS
Patients, cell lines, and peptides
PBMCs were isolated from 20 ml of heparinized blood of HLA–
A24
+ (n=55) and HLA–A2
+ (n=25) cancer patients (40 gastric, 15
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www.bjcancer.comcolon, 11 lung, seven gynaecological, three prostate cancers, and four
melanomas) by means of Ficoll–Conray density gradient centrifuga-
tion as reported previously (Gomi et al, 1999). Among them, 56
patients had no distant metastases and 24 patients had distant metas-
tases. No patient had undergone any immunotherapy or
chemotherapy at least for 1 month before sampling. Complete
informed consents were obtained from all patients. PBMCs were also
obtained from 31 healthy volunteers (20 HLA–A24
+ and 11 HLA–
A2
+). HLA-class-I typing was performed on blood lymphocytes
using the classical serological method, as reported previously (Gomi
et al, 1999). The tumour cell lines used in this study are as follows:
KWS (HLA-A0206/0206), SSTW9 (A2402/2601) gastric adenocarci-
noma, Panc-1 (A0201/0206) pancreatic adenocarcinoma, and
SW620 (A0201/2402) colon adenocarcinoma. PHA-activated normal
T cells were also used as target. Peptides used in this study are listed
in Table 1 for HLA-A24-restricted peptides, and in Table 2 for HLA-
A2-restricted peptides. All peptides except for Epstein–Barr virus
(EBV)- and Inﬂuenza virus (Flu)-derived peptides are encoded by
tumour-rejection antigens, and have the ability to induce HLA-
A24 or -A2-restricted CTLs speciﬁc to tumour cells in PBMCs of
cancer patients, as reported previously (Shichijo et al, 1998; Gomi
et al, 1999; Yang et al, 1999; Ito et al, 2000, 2001; Kawano et al,
2000; Nakao et al, 2000; Nishizaka et al, 2000; Harashima et al,
2001; Tamura et al, 2001). These peptides were purchased from
Sawady Laboratory (Tokyo, Japan), and their purity was 495%.
Detection of CTL-precursors
A simple method was used to detect peptide-speciﬁc CTLs in
PBMCs (Hida et al, 2002). PBMCs (1610
5 cells per well) were
incubated with 10 mM of a peptide in wells of the u-bottom-type
96-well microculture plates (Nunc, Roskilde, Denmark) in 200 ml
of culture medium. The culture medium consisted of 45%
RPMI-1640 medium, 45% AIM-V
1 medium (GIBCO–BRL),
10% FCS, 100 U ml
71 of interleukin-2 (IL-2), and 0.1 mM MEM
nonessential amino acid solution (GIBCO–BRL). Half of the
medium was removed and replaced with the new medium contain-
ing a corresponding peptide (20 mM) every 3 days. After incubation
for 12 days, these cells were harvested and then tested for their
ability to produce IFN-g in response to CIR-A2402 cells pre-loaded
with either a corresponding peptide or HIV peptide (RYLRQQLL-
GI) as a negative control in HLA-A24
+ PBMCs, or those in
response to T2 cells pre-loaded with a corresponding or HIV
peptide (SLYNTYATL) in HLA-A2
+ PBMCs by an enzyme-linked
immuno-sorbent assay (ELISA) (limit of sensitivity: 10 pg ml
71).
All experiments were performed in quadricate assays. Detectable
levels of CTL-precursors were judged as positive (the score is
in bold in Tables) if the mean value of IFN-g production by
the peptide-stimulated PBMCs in response to a corresponding
peptide was signiﬁcantly (P50.05) higher than that in response
to control HIV peptide. A two-tailed Student t-test and
Fisher’s exact probability test were employed for the statistical
analyses.
Cyototoxicity assay of the peptide-induced CTLs
The peptide-stimulated PBMCs were further incubated in the
presence of feeder cells for 3 weeks in order to obtain a relatively
large number of cells, and were tested for their cytotoxicity against
various target cells by a standard 6 h
51Cr-release assay. For an
inhibition assay, the
51Cr-release assay was performed in the
presence of 20 mgm l
71 of anti-CD8, -CD4, -HLA-class I (W6/
32), or -HLA-class II (DR) mAb. A standard CTL precursor
frequency analysis was performed in certain cases, and the detailed
description of this method is reported elsewhere (Miyagi et al,
2001). Brieﬂy, cells were incubated at 12.5, 25, 50, 100, 200 and
400 cells per well of 96-well microculture plate in the presence of
feeder cells. Cells from each well were harvested and tested at 9
to 15 days of culture in duplicate assay for their ability to produce
IFN-g by recognition of peptide-pulsed target cells. The well was
considered positive if it contained effector cells producing much
higher levels (4100 pg ml
71) and also statistically signiﬁcant levels
(P50.05 by Student t-test) of IFN-g in response to CIR-
A2402 cells (or T2 cells for HLA-A2 cases) pre-loaded with a corre-
sponding peptide as compared with those in response to CIR-
A2402 cells (or T2 cells) pre-loaded with control HIV peptide.
Data were analysed by the minimum w
2 method with 95% conﬁ-
dence intervals, and the CTL precursor frequency was calculated
by Taswell’s method (Taswell, 1981).
RESULTS
CTL-precursors in gastric cancer patients
PBMCs of cancer patients (n=80; 40 gastric, 15 colon, 11 lung,
seven gynecological, three prostate cancers, and four melanomas)
and healthy donors (n=31) were tested for their reactivity to a
corresponding peptide after stimulation with each peptide.
Results regarding HLA-A24
+ (n=20) and -A2
+ (n=20) gastric
cancer patients are shown in Tables 1 and 2, respectively. PBMCs
from 16 of 20 HLA-A24
+ gastric cancer patients possessed CTL-
precursors reactive to at least one of 13 peptides of vaccine
candidates tested (Table 1). Among these 16 patients, ﬁve, one,
three, six and one patients had CTL-precursors reactive to one,
two, three, four and ﬁve peptides of vaccine candidates, respec-
tively. The mean number of positive peptides was 2.8 per
patient. Seven and six patients had CTL-precursors reactive to
ART475 and SART3109 peptides, respectively. Four patients had
detectable levels of CTL-precursors to SART2899, SART3315,
lck208 and lck488 peptides. CTL-precursors to the other seven
peptides were also detectable in several patients. The proﬁle of
positive peptides entirely varied in 16 patients. In contrast,
CTL-precursors reactive to these peptides were undetectable in
PBMCs of the remaining four cancer patients. It is of note that
CTL-precursors reactive to either Flu- or EBV-peptide, taken as
positive control peptide, were also undetectable in PBMCs from
those four cancer patients.
PBMCs from 11 of 20 HLA-A2
+ gastric cancer patients
possessed CTL-precursors reactive to at least one of 15 peptides
of vaccine candidates tested (Table 2). Among them, ﬁve, one,
three, one and one patients had CTL-precursors reactive to one,
two, three, four and seven peptides, respectively. The mean number
of positive peptides was 2.3 peptides per patient. Four patients had
CTL-precursors reactive to HNRPL140 peptide, while three patients
had those reactive to SART3302 and SART3309 peptides. CTL-
precursors were also found to the others except one
(ppMAPkkk432) peptide with lower frequencies. The proﬁle of
positive peptides was also entirely different among 11 patients. In
contrast, CTL-precursors reactive to these peptides were undetect-
able in the remaining nine patients. Among them, seven patients
had no detectable level of CTL-precursor reacting to either Flu-
or EBV-peptide.
Cytotoxicity of peptide-induced CTLs
A standard 6 h
51Cr-release assay was employed to conﬁrm the
anti-tumour response of the peptide-induced CTLs in four cancer
patients. PBMCs of Pt 2 (HLA-A24
+) showed signiﬁcant levels of
cytotoxicity against HLA-A24
+ tumour cells (SW620 and
SSTW9), but not against HLA-A24
7 tumour cells (Panc1 and
KWS) or normal PHA-blastoid T cells, when they were stimu-
lated with each of the positive peptides derived from cancer-
related antigens (SART3109, lck208, and lck488) (Figure 1A and
Table 3). In contrast, those stimulated with either EBV peptide
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
Peptide-specific CTL-precursors
Y Maeda et al
797
ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(7), 796–804or any of the negative peptides (SART3315, lck486, ART413, and
ART475) were not cytotoxic to any of the target cells tested.
Similar results were obtained in the PBMCs of Pt 18 who had
CTL-precursors reactive to EBV, SART3109, SART3315, and
ART475 (Figure 1A and Table 3). PBMCs of Pt 35 (HLA-A2
+)
possessed CTL-precursors reacting to Flu, EBV, SART3302,
HNRPL140 and the other ﬁve peptides (Table 2). Those PBMCs
stimulated with SART3302 and HNRPL140 also showed HLA-A2-
restricted and tumour-speciﬁc CTL activities (Figure 1B), whereas
those stimulated with Flu, EBV, or any of the negative peptides
had no CTL activity (data not shown). Similarly, PBMCs of
Pt 39 had CTL-precursors reactive to Flu, EBV, and HNRPL501
peptides, and those stimulated with HNRPL501 peptide (Figure
1B), but not those with the other peptides (Flu, EBV, or negative
peptides), showed HLA-A2-restricted and tumour-speciﬁc CTL
activity. These CTL activities were inhibited by either anti-class
I or -CD8 monoclonal antibody (mAb), but not by the other
mAbs tested (data not shown).
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Table 1 Induction of peptide-speciﬁc CTLs from PBMCs of HLA-A24
+ gastric cancer patients
Peptide-speciﬁc IFN-g production (pg ml
71)
HLA-A24
+ gastric cancer patients
Peptide Sequence Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6 Pt 7 Pt 8 Pt 9 Pt10 Pt11 Pt12 Pt13 Pt14 Pt15 Pt16 Pt17 Pt18 Pt19 Pt20
Flu RFYIQMCYEL 0 11 NT 2 0 0 0 16 0 0 0 0 0 0 0 0 0 37 0 0
EBV TYGPVFMCL 0 392 11 16 6 0 0 15 0 0 0 244 10 0 11 0 0 109 00
SART1 690 EYRGFTQDF 46 90900 0 0 00 0 159 00 3 0 94 0 0 21 5
SART2 93 DYSARWNEI 0 24 NT 31 15 0 0 0 13 0 0 0 0 0 21 0 127 0 156 0
SART2 161 AYDFLYNYL 0 0 NT 0 18 911 00 0 1 9 0 146 20 0 170 0 0 12 0
SART2 899 SYTRLFLIL 0 0 NT 4 142 42 0 0 0 0 0 38 330 0096 00 208 0
SART3 109 VYDYNCHVDL 65 375 240 53 0 218 0 258 00 0 2 6 3 400 0 2 5 93 69 0
SART3 315 AYIDFEMKI 17 0 2 18 31 0 0 285 0 0 13 0 25 0 15 11 113 102 350 0
CyB 84 KFHRVIKDF 123 04 70 17 0 60 0 0 0 0 19 37 0 0 0 0 0 64 0
CyB 91 DFMIQGGDF 000000 3 0 00 0 0 626 00 0 0 07 6 0
lck 208 HYTNASDGL 93 117 0 0 26 0 0 0 0 0 330 79 170 14 0 0 65 11 0 0
lck 486 TFDYLRSVL 0 0 0 22 0 0 0 125 0 0 14 2 20 0 10 0 63 40 0
lck 488 DYLRSVLEDF 0 181 0 147 0 14 0 0 11 0 27 28 0 151 0 66 080 0
ART4 13 AFLRHAAL 0 0 NT 21 13 325 40 00 132 0 488 46 0 0 0 0 4 0
ART4 75 DYPSLSATDI 0 0 NT 113 0 266 4 331 0058 18 131 06 3 0 1 9 73 97 0
EBV: Epstein-Barr virus; SART: squamous cell carcinoma antigen recognized by T cells; CyB: Cyclophilin B; ART: adenocarcinoma antigen recognized by T cells. PBMCs of HLA-
A24
+ gastric cancer patients were tested for their reactivity to a corresponding peptide after stimulation with each peptide. Values represent the means of quadricate assays of
IFN-g production (pg ml
71) by the effector PBMCs in response to CIR-A2402 cells pulsed with a corresponding peptide. Background IFN-g production in response to HIV
peptide (0–200 pg ml
71) was subtracted. Detectable levels of CTL-precursors were judged as positive (the score is in bold ﬁgures in Tables) if the mean value of IFN-g
production by the peptide-stimulated PBMCs in response to a corresponding peptide was signiﬁcantly (P50.05, by two-tailed student t-test) higher than that in response
to HIV peptide. NT: Not tested.
Table 2 Induction of peptide-speciﬁc CTLs from PBMCs of HLA-A2
+ gastric cancer patients
Peptide-speciﬁc IFN-g production (pg ml
71)
HLA-A2
+ gastric cancer patients
Peptide Sequence Pt21 Pt22 Pt23 Pt24 Pt25 Pt26 Pt27 Pt28 Pt29 Pt30 Pt31 Pt32 Pt33 Pt34 Pt35 Pt36 Pt37 Pt38 Pt39 Pt40
Flu GILGFVFTL 0 8 NT NT NT NT 0 110 268 37 560 NT NT NT 15005 01 5 316 478 101
EBV GLCTLVAML 0 356 35 7 55 28 79 03 6 0 00 405 14 323 23 0 83 849 0
SART3 302 LLQAEAPRL 0 0 9 16 0 212 01 2 600 0 5 6 3 100 NT 14 777 06 4
SART3 309 RLAEYQAYI 6 0 0 52 0 195 134 0 75 0 0 0 24 0 74 NT 13 3 0 61
CyB 129 KLKHYGPGWV 0 40 NT NT 0 11 66 0 33 0 346 NT NT 0 58 20 33 0 0 13
CyB 172 VLEGMEVV 0 38 18 14 0 0 0 0 27 0 0 0 0 86 63 NT 17 12 0 0
lck 246 KLVERLGAA 0 20 16 0 0 0 210 73 3 080 0 0 0 3 3 3 8 2 9 000
EIF4EBP1 51 RIIYDRKFL 0 0 NT NT NT 79 0 63 21 20 0 NT NT NT 14 NT 5 172 03
ppMAPkkk 294 GLLFLHTRT NT NT 0 27 0 126 76 0 10 0 NT 91 14 0 19 NT 9 0 0 8
ppMAPkkk 432 DLLSHAFFA NT NT 5 6 0 9 65 2 16 14 NT 4 4 8 0 NT 0 0 0 22
WHSC2 103 ASLDSDPWV NT NT 16 0 0 33 20 0 9 207 NT 18 0 0 53 NT 28 0 0 12
WHSC2 141 ILGELREKV NT NT 0 0 0 1 33 0 16 4 NT 5 15 0 53 NT 10 0 0 0
UBE2V 43 RLQEWCSVI NT NT 0 5 0 56 110 25 96 28 NT 0 20 0 3 NT 12 29 0 0
UBE2V 85 LIADFLSGL NT NT 85 13 0 206 24 0 16 81 N T01 9 0 0 N T0 004
UBE2V 208 ILPRKHHRI NT NT NT NT NT NT 7 2 0 56 NT NT NT NT NT NT 5 0 0 86
HNRPL 140 ALVEFEDVL NT NT 100 13 0 17 0 57 22 63 NT 0 7 0 401 NT 0 0 0 57
HNRPL 501 NVLHFFNAPL NT NT 8 0 6 06005 N T02 0 0 0 N T0 0 253 0
EIF4EBP: eIF-4E-binding protein; ppMAPkkk: partial putative mitogen-activated protein kinase kinase kinase; WHSC2: Wolf-Hirschhorn syndrome candidate 2 protein; UBE2V:
ubiquitin-conjugated enzyme variant Kua; HNRPL: heterogeneous nuclear ribonucleoprotein L. PBMCs of HLA-A2
+ gastric cancer patients were tested for their reactivity to a
corresponding peptide after stimulation with each peptide. Values represent means of quadruplicate assays of IFN-g production (pg ml
71) by the effector PBMCs in response to
T2 cells pulsed with a corresponding peptide. Background IFN-g production in response to HIV peptide (0–200 pg ml
71) was subtracted. Detectable levels of CTL-precursors
were judged as positive (the score is in bold ﬁgures in Tables) if the mean value of IFN-g production by the peptide-stimulated PBMCs in response to a corresponding peptide
was signiﬁcantly (P50.05, by two-tailed student t-test) higher than that in response to HIV peptide. NT: Not tested.
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A standard CTL precursor frequency analysis by limiting dilution
method was performed in certain cases to compare the results
obtained by the new culture method for CTL-induction. Represen-
tative results are shown in Figure 2. PBMCs of Pt 35 stimulated
with EBV peptide by the new method were provided as a positive
control at 400, 200, 100, 50, 25 and 12.5 cells per well for CTL-
precursor frequency analysis in duplicate assay. CTL-precursors
were detectable in all 96 wells when cells were harvested from wells
of 400 and 200 cells per well. CTL-precursors were detectable in 94,
88, 77 and 30 wells when cells were harvested from wells of 100,
50, 25 and 12.5 cells per well (Figure 2A). Subsequently the
CTL-frequency was evaluated as at least 41 out of 100. Unstimu-
lated PBMCs from the same patient were directly provided for
CTL-precursor analysis in response to EBV and SART3302 peptide
to which CTL-precursors were detectable by means of our culture
method (Pt 35 in Table 2). Precursor frequencies of EBV and
SART3302 peptide-speciﬁc CTL were found to be one out of
2525 and one out of 7621, respectively (Figure 2B). Unstimulated
PBMCs of Pt 2 were also provided for CTL-precursor analysis in
response to SART3109, lck208 and ART475 peptides. CTL-precursors
to any of these three peptides were under detectable levels (51 out
of 26063) in this precursor frequency analysis. However, CTL-
precursors reactive to the positive peptides (SART3109 and lck208)
were found in one or two wells and no positive well was detected
for the negative (ART475) (Figure 2C).
CTL-precursors in other cancer patients and healthy
donors
The results of the induction assay regarding cancer patients other
than those with gastric cancer are shown in Table 4 (HLA-A24
+
10 colon, 11 lung, seven gynecological, three prostate cancer, and
four melanoma patients) and in Table 5 (HLA-A2
+ ﬁve colon
cancer patients). The same CTL-induction assay was also
performed for 31 healthy donors (20 HLA-A24
+ donors and 11
HLA-A2
+ donors). Overall reactivity to each peptide in all 80
cancer patients and in 31 healthy donors is shown in Table 6.
CTL-precursors reactive to at least one of the vaccine-candidate-
peptides were detectable in 57 out of 80 patients (71%), and the
mean numbers of positive peptides were 2.0 peptides per positive
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Figure 1 Peptide-induced CTL activity. PBMCs stimulated with peptides were expanded in the presence of feeder cells for 21–25 days, and were tested
for their cytotoxicity against various target cells by a 6 h
51Cr-release assay. Representative results of HLA-A24
+ and -A2
+ patients are shown in (A) and (B)
respectively.
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peptides of vaccine candidates varied among these 57 patients,
and seemed not to be inﬂuenced by the cancer origin. CTL-precur-
sors reacting to cancer-related peptides were also detectable in 20
out of 31 healthy donors (64%), and the mean number of positive
peptides in each donor was 1.4 (ranging from 1–4 peptides).
The percentages of detection of CTL-precursors reacting to
foreign antigen peptide (Flu and EBV) in cancer patients were
signiﬁcantly lower than those in healthy donors in HLA-A24 cases
(Table 6, left column). Those of EBV-speciﬁc CTL-precursors in
cancer patients were also signiﬁcantly lower than those in healthy
donors in HLA-A2 cases (Table 6, right column). In contrast,
the percentages of cases having CTL-precursors reactive to
SART3315 and lck488 peptides in HLA-A24
+ patients were signiﬁ-
cantly higher than those in HLA-A24
+ healthy donors (Table 6,
left column). A similar trend was also observed in certain WHSC2-
and UBE2V-derived peptides in HLA-A2
+ patients (Table 6, right
column).
DISCUSSION
We have demonstrated in the present study that peptide-speciﬁc
CTL-precursors are detectable in the majority of cancer patients,
and that PBMCs incubated with the positive peptides, not with
the negative peptides, show signiﬁcant levels of HLA-class-I-
restricted cytotoxicity to cancer cells. These results suggest that
vaccination of the positive peptides to cancer patients induces more
potent anti-tumour response than that of the negative peptides.
Twenty-eight peptides (13 for HLA-A24
+ and 15 for HLA-A2
+
cancer patients) were used in this study. There are, however, many
other peptides that are vaccine candidates having the ability to
induce HLA-class-I-restricted CTLs reactive to cancer cells. There-
fore, increased numbers of peptides for the assay should lead to an
increase in the number of patients having CTL-precursors reactive
to peptides and in the number of positive peptides per patient.
These two HLA-class I alleles (HLA-A24 and -A2) are observed
in 470% of Caucasians, 480% of Asians, and 440% of Blacks
(Imanishi et al, 1992; Tokugawa et al, 1997). The present study also
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Table 3 Cytotoxicity of peptide-stimulated CTLs from cancer patients
Cytotoxicity (% lysis)
Peptide-speciﬁc INF-g SW620 SSTW9 Panc-1 KWS PHA-T cell PHA-T cell
Patient Peptide production (pg ml
71) (A24+) (A24+) (A247) (A247) (A24+) (A247)
Patient 2 EBV 392 55 55 55 55 55 55
SART3109 375 34 28 55 55 55 55
SART3315 0 55 55 55 55 55 55
lck208 117 32 22 55 55 55 55
lck486 0 55 55 55 55 55 55
lck488 181 29 19 55 55 55 55
ART413 0 55 55 55 55 55 55
ART475 0 55 55 55 55 55 55
Patient 18 EBV 109 55 55 55 55 55 55
SART3109 93 21 18 55 55 55 55
SART3315 102 24 18 55 55 55 55
lck208 0 55 55 55 55 55 55
lck486 0 55 55 55 55 55 55
lck488 0 55 55 55 55 55 55
ART413 0 55 55 55 55 55 55
ART475 73 28 22 55 55 55 55
Peptide-induced CTLs from PBMCs of cancer patients were tested for their cytotoxicity against various cells by standard 6 h
51Cr-release assay at E/T of 40/1. Values represent
means of triplicate assay.
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Figure 2 Precursor frequency analysis by limiting dilution method. PBMCs of a cancer patient (Pt 35) cultured with EBV peptide for 10 days by the new
culture method (A), unstimulated PBMCs of the same patient (B) and unstimulated PBMCs of another cancer patient (Pt 2) (C) were served for limiting
dilution culture as described in Materials and Methods. Cells from each well were tested at 9 to 15 days of culture for IFN-g production in the presence of
target cells. Wells were considered positive if they contained effector cells producing much higher level (4100 pg ml
71) and also statistically signiﬁcant
levels (P50.05 by two-tailed Student-t test) of IFN-g in response to CIR-A2402 or T2 cells pre-loaded with a corresponding peptide as compared with
IFN-g levels in response to CIR-A2402 or T2 cells pre-loaded with HIV peptide in duplicate assay. Data were analysed by the minimum w
2 method with 95%
conﬁdence intervals, and the CTL precursor frequency was calculated by Taswell’s method.
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and that there is no obvious correlation regarding the types of
cancers tested (gastric, colon, lung, gynaecological, and prostate
cancers, and melanomas) or clinical stages (presence or absence
of distant metastasis). Therefore, CTL-precursors reactive to
peptides of vaccine candidates could be detectable in PBMCs of
a large number of cancer patients throughout the world, regardless
of cancer origin or clinical stage.
It is important to determine whether or not detection of
peptide-speciﬁc CTL-precursors was associated with the expres-
sion of corresponding antigen in individual cancer patients.
However, most epithelial cancer patients enrolled in this study
were inoperable and availability of tumour samples was very
limited in contrast to melanoma patients. In regard with
SART-1, -2, -3, and ART4 antigens, we previously reported
their protein expression in many samples of the majority of
epithelial cancer cells and tissues by Western blot and Northern
analyses (Shichijo et al, 1998; Yang et al, 1999; Nakao et al,
2000). We also reported that lck antigen was expressed in the
majority of metastatic cancer cells and tissues (Harashima et
al, 2001).
Difference in afﬁnities of the peptides to the HLA-class I mole-
cules might affect the efﬁcacy of in vitro sensitization of PBMCs
from cancer patients. In regard to peptides derived from either
SART2 or SART3, their scores, an estimated half-time dissociation
determined by computer program (Parker et al, 1994), were
compared and it was found that peptides with higher scores
seemed to induce peptide-speciﬁc CTLs more efﬁciently than those
with lower scores (unpublished observation).
PBMCs from healthy donors also had CTL-precursors to
peptides of vaccine candidates with relatively lower frequency,
which was expected from our previous results showing that all
the tumour-rejection antigens, from which the peptides originated,
used in this study are non-mutated self-antigens preferentially
expressed in proliferating cells, including malignant and normal
cells (Yang et al, 1999). However, CTLs induced by these peptides
showed cytotoxicity against cancer cells, but not against normal
proliferating cells, as also demonstrated previously (Yang et al,
1999). Therefore, vaccination of these peptides may not be asso-
ciated with adverse events in normal cells and normal tissues.
Indeed, no severe adverse events have been observed in phase I
clinical studies at the Kurume University Hospital, where 13 differ-
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Table 4 Induction of peptide-speciﬁc CTLs from PBMCs of HLA-A24
+ cancer patients (colon, lung, gynaecological, prostate, and melanoma)
Peptide-speciﬁc IFN-g production (pg ml
71)
HLA-A24
+ colon cancer patients HLA-A24
+ lung cancer patients
Peptide Pt41 Pt42 Pt43 Pt44 Pt45 Pt46 Pt47 Pt48 Pt49 Pt50 Pt51 Pt52 Pt53 Pt54 Pt55 Pt56 Pt57 Pt58 Pt59 Pt60 Pt61
Flu 28 0 0 0 0 0 33 7 0 0 104 00 0 00 0 0 200 00
EBV 231 80 0 2 9 0 0 0 0 6 34 9 0 062 0 0 38 10 188 00
SART1 690 14 60 0 0 0 246 0 0 11 38 53 0 81 32 30 0 0 0 46 0 0
SART2 93 0 68 0 0 18 16 26 13 0 15 68 0 0 26 0 0 0 0 0 0 0
SART2 161 139 56 0 0 40 0 17 19 0 0 19 5 0 0 0 0 0 72 106 00
SART2 899 225 109 0 0 41 6 29 0 4 0 18 22 0 16 0 0 0 108 95 00
SART3 109 325 170 0 109 61 0 0 19 26 15005 0 297 00 0 0 0 125 00 0
SART3 315 17 104 0 0 45 0 39 0 26 15 108 77 0 0 0 0 0 87 00126
CyB 84 248 56 0 0 66 00 05 0 171 35 217 00 198 0 59 30 19 0 0
CyB 91 05 80 0 56 14 14 9 0 4 111 129 00 0 6 4 3 10 1 8 0 0
lck 208 349 50 3 53 6 9 25 15 0 74 84 00 180 0 0 44 24 0 0
lck 486 161 0 0 0 29 0 51 23 58 0 100 126 22 0 48 0 0 43 26 0 0
lck 488 310 13 0 100 45 24 9 0 0 19 122 133 00 172 0 130 04 60 0
ART4 13 00 0 0 64 72 9 0 70 0 114 105 10 0 50 0 130 02 60 0
ART4 75 02 10 0 59 06 02 5 0 122 128 70 0 0 113 00 0 0
Table 4 continued
HLA-A24
+ gynaecological cancer patients
HLA-A24
+ prostate
cancer patients HLA-A24
+ melanoma patients
Pt62 Pt63 Pt64 Pt65 Pt66 Pt67 Pt68 Pt69 Pt70 Pt71 Pt72 Pt73 Pt74 Pt75
Flu 0 0 14 0 248 05 0 0 0 00 00
EBV 0 0 0 0 19 75 00 147 0 311 138 00
SART1 690 67 14 0 142 21 0 33 0 0 0 7 0 0 0
SART2 93 30 0 0 112 175 16 9 0 0 0 0 0 0 0
SART2 161 12 0 365 10 0 7 84 17 0 0 98 00 0
SART2 899 0 105 182 0 0 24 0 0 10 0 25 0 0 0
SART3 109 00 0 3 0 101 002 0 0 0 99 00
SART3 315 0 0 18 0 0 11 157 0 66 00 0 0 0
CyB 84 2 0 604000 1 4 0 0 00 00
CyB 91 0 000000 0 0 01 60 00
lck 208 0 0 13 0 318 0 76 00 0 0 0 0 0
lck 486 20 0 0 250 00 0 0 069 00 0
lck 488 07 172 0 142 00 76 00 0 00 0
ART4 13 0 000000 0 0 0 215 00 0
ART4 75 0 00000 1 8 0 0 0 0 110 00
Sequence of each peptide is shown in Table 1.
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HLA-A24
+ cancer patients as peptides vaccines in vivo (Miyagi et
al, 2001, and the other unpublished data).
Peptide-speciﬁc CTL-precursors were detected in healthy
donors. One might wonder whether CTL-precursors of cancer
patients are distinguishable from those of healthy donors or not.
We observed that CyB peptide-stimulated CTLs from cancer
patients had a tendency to show both peptide-speciﬁc and
tumour-reactive responses, but those from healthy donors seemed
to exhibit peptide-speciﬁc responses but no tumour-reactive
response (Gomi et al, 1999). We suppose that, in healthy donors,
CTL-precursors reacting to CyB peptides were primed as a result
of cross-reactivity of CyB to bacteria-derived exogenous antigens
(Ohkouchi et al, 2002). We also repeatedly reported that
peptide-stimulated PBMCs from certain healthy donors produced
signiﬁcant levels of IFN-g in response to peptides, but rarely
showed cytotoxicity against tumour cells in an HLA-A24 or -A2
restricted manner by means of a
51Cr-release assay (Harashima et
al, 2001; Ito et al, 2000, 2001; Kawano et al, 2000; Nishizaka et
al, 2000). In addition, peptide-speciﬁc CTLs from cancer patients
proliferated well for a long time in culture with IL-2 alone and
thus these expanded cells became available in use for a
51Cr-release
assay, whereas those from healthy donors did not (unpublished
data). Therefore, measurement of CTL activity with a standard
51Cr-release assay could be a good tool to distinguish CTL-precur-
sors of cancer patients from those of healthy donors.
There is a possibility that vaccination with a given peptide could
result in in vivo immunoselection of host tumour in situ, and that
further boosting against such epitopes might be unsuccessful. Jager
et al (1996) reported an inverse correlation of antigen expression
and CTL response in patients with metastatic melanoma (Jager et
al, 1996). However, as described in the Introduction, we undertook
this study to determine whether CTL precursors were detectable at
the prevaccination state, based on the idea that boosting of circu-
lating CTL precursors could be more reasonable than newly
priming of CTLs. We suppose that an appropriate clinical trial is
needed to answer to this key question. A phase I study of CTL-
precursor-oriented vaccine, in which prevaccination PBMCs were
screened in vitro for their reactivity to each of the peptides
followed by vaccination of only the positive peptides, has been in
progress since November 2000 at Kurume University. The initial
study of immune responses to both peptides and tumour cells in
post-vaccination PBMCs of colorectal cancer patients suggested
that the present regime could be superior to the conventional
regime to elicit prompt and strong immune responses.
CTL-precursors detected by this new culture method were also
detectable by the standard CTL-precursor analysis in the Pt 35 case,
but not in the Pt 2 case. Therefore, the limit of sensitivity of the new
method may be higher than that of the conventional CTL-precursor
frequency analysis. PBMCs were stimulated ﬁve or 0 times before
the assay by the new method or by CTL-precursor frequency analy-
sis, respectively, which might have inﬂuenced the limit of sensitivity.
The limit of sensitivity of the standard CTL-precursor analysis is one
out of 26063 (Taswell, 1981), whereas the limit of sensitivity of the
new method used in this study is one out of 100000 (Hida et al,
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Table 5 Induction of peptide-speciﬁc CTLs from PBMCs of HLA-A2
+
colon cancer patients
Peptide-speciﬁc IFN-g production (pg ml
71)
HLA-A2
+ colon cancer patients
Peptide Pt76 Pt77 Pt78 Pt79 Pt80
Flu NT 285 06 327
EBV 0 134 000
SART3 302 1 98000
SART3 309 140 71 7 050
CyB 129 97000
CyB 172 0 102 540
lck 246 00 1 800
EIF4EBP1 51 03 0 230 09
ppMAPkkk 294 34 215 030
ppMAPkkk 432 61 14 35 189 0
WHSC2 103 33 7 14 5 0
WHSC2 141 26 30 9 111 0
UBE2V 43 00 147 00
UBE2V 85 00000
UBE2V 208 NT 0 108 12 0
HNRPL 140 10 0 122 10 0
HNRPL 501 00070
Sequence of each peptide is shown in Table 2.
Table 6 Percentage of peptide-speciﬁc CTL-induction
Positive percentage of induction of peptide-speciﬁc CTLs (%)
HLA-A24-restricted peptides HLA-A2-restricted peptides
Cancer patients Healthy donors Cancer patients Healthy donors
Flu 14 (4 out of 55) / P50.05 ? 40 (8 out of 20) Flu 53 (9 out of 17) 80 (8 out of 10)
EBV 16 (9 out of 55) / P50.01 ? 65 (13 out of 20) EBV 29 (7 out of 24) / P50.05 ? 72 (8 out of 11)
SART1690 9 (5 out of 55) 20 (4 out of 20) SART3302 13 (3 out of 24) 27 (3 out of 11)
SART293 7 (4 out of 55) 15 (3 out of 20) SART3309 21 (5 out of 24) 0 (0 out of 11)
SART2161 16 (9 out of 55) 10 (2 out of 20) CyB129 10 (2 out of 21) 0 (0 out of 10)
SART2899 18 (10 out of 55) 15 (3 out of 20) CyB172 8 (2 out of 24) 9 (1 out of 11)
SART3109 27 (15 out of 55) 10 (2 out of 20) lck246 8 (2 out of 25) 9 (1 out of 11)
SART3315 19 (10 out of 55) / P50.05 ? 0 (0 out of 20) EIF4EBP151 17 (3 out of 18) 20 (2 out of 10)
CyB84 16 (9 out of 55) 10 (2 out of 20) ppMAPkkk294 10 (2 out of 21) 18 (2 out of 11)
CyB91 7 (4 out of 55) 20 (4 out of 20) ppMAPkkk432 5 (1 out of 21) 0 (0 out of 11)
lck208 18 (10 out of 55) 10 (2 out of 20) WHSC2103 10 (2 out of 21) 0 (0 out of 11)
lck486 15 (8 out of 55) 10 (2 out of 20) WHSC2141 10 (2 out of 21) 0 (0 out of 11)
lck488 24 (13 out of 55) / P50.05 ? 0 (0 out of 20) UBE2V43 14 (3 out of 21) 0 (0 out of 11)
ART413 16 (9 out of 55) 20 (4 out of 20) UBE2V85 10 (2 out of 21) 9 (1 out of 11)
ART475 22 (12 out of 55) 20 (4 out of 20) UBE2V208 17 (2 out of 12) 0 (0 out of 9)
HNRPL140 24 (5 out of 21) 18 (2 out of 11)
HNRPL501 5 (1 out of 21) 0 (0 out of 11)
Fisher’s exact probability test was used for statistical analysis between cancer patients and healthy donors.
Peptide-specific CTL-precursors
Y Maeda et al
802
British Journal of Cancer (2002) 87(7), 796–804 ã 2002 Cancer Research UK2002). The speciﬁcity and positive predictive value of the CTL
induction system used in this study were found to be high enough
for clinical use (90 and 100%, respectively) (data not shown). The
CTL induction method used in this study also has some other
advantages compared to the standard CTL-precursor analysis or
the tetramer method. The cost of the standard CTL-precursor analy-
sis is more than 10 times that of the method used in this study
(approximately $500 vs $30, per peptide, respectively), and the stan-
dard CTL-precursor analysis requires large number of feeder cells so
that the inﬂuence of allogeneic feeder cells may not be entirely
excluded. Although a tetramer assay is an alternative method, it does
not directly reﬂect the functional activity of CTLs such as that
reﬂected by cytotoxicity or cytokine production.
In conclusion, this study has showed that peptide-speciﬁc CTL-
precursors are detectable in PBMCs of cancer patients prior to
vaccination, thus providing a scientiﬁc basis for the development
of a CTL-precursor-oriented peptide vaccine as an order-made
cancer immunotherapy for the majority of cancer patients through-
out the world. The same vaccine strategy may be applicable to
patients infected with HIV or other pathogenic viruses, for which
no effective vaccine is available.
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